Advertisement
Singapore markets closed

  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,871.64
    -5.41 (-0.07%)
     

  • Bitcoin USD

    64,316.90
    +604.93 (+0.95%)
     

  • CMC Crypto 200

    1,367.93
    +55.30 (+4.40%)
     

  • S&P 500

    4,999.37
    -11.75 (-0.23%)
     

  • Dow

    37,965.53
    +190.15 (+0.50%)
     

  • Nasdaq

    15,455.47
    -146.03 (-0.94%)
     

  • Gold

    2,402.20
    +4.20 (+0.18%)
     

  • Crude Oil

    83.18
    +0.45 (+0.54%)
     

  • 10-Yr Bond

    4.6270
    -0.0200 (-0.43%)
     

  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     

  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

This Pharma's Sales Are So Hot It's Trying to Curb Demand

Alex Carchidi, The Motley Fool
·4-min read
This Pharma's Sales Are So Hot It's Trying to Curb Demand

Novo Nordisk (NYSE: NVO) is planning to pause some of its advertising campaigns for its obesity drug Wegovy, due to white-hot demand in the U.S. The impact of the move isn't the marketing costs it saves, but the unambiguous message it sends: Wegovy is probably going to bring in even more sales than management expected -- and it had expected quite a bit. This isn't the first time that demand for Wegovy has been greater than what the pharma can manufacture, and it's no surprise why.

Continue reading